Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots [Seeking Alpha]
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: Seeking Alpha
OV329 Phase 2a in drug-resistant focal seizures is planned for Q2 2026. And we should get its topline data by mid-2027. OVID's KCC2 program leads with OV4071, which targets PD/LBD psychosis and schizophrenia. Its IND is expected by Q1 2026, and its Phase 1 by Q2 2026. The company's recent $175M PIPE extends its runway into 2028. This derisked OVID's prospects and allowed them to see through their near-term milestones. OVID's valuation multiples post-PIPE seem cheap, and when you consider its pipeline's optionality, I believe the stock is compelling at these levels. Richard Drury/DigitalVision via Getty Images Ovid Therapeutics Inc. ( OVID ) is a CNS drug developer that focuses on therapies to treat disorders linked to neuronal hyperexcitability. OVID's pipeline is mostly focused on two mechanisms: 1) a GABA-AT inhibitor for uncontrolled epilepsy and 2) KCC2 This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OVID&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $4.00 price target on the stock.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.MarketBeat
- Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) [Yahoo! Finance]Yahoo! Finance
OVID
Earnings
- 11/12/25 - Miss
OVID
Sec Filings
- 1/29/26 - Form SCHEDULE
- 1/8/26 - Form SCHEDULE
- 1/5/26 - Form 4
- OVID's page on the SEC website